Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03692403
Other study ID # 000165
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 26, 2018
Est. completion date February 14, 2022

Study information

Verified date October 2022
Source Ferring Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date February 14, 2022
Est. primary completion date February 14, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pre-menopausal females aged =18 years at time of signing informed consent(s) with regular menstrual cycles. - Body mass index (BMI) of 18-42 kg/m2 (both inclusive) at screening. - Initial confirmation of endometriosis by laparoscopy or laparotomy within the last 10 years before the run-in visit or visualization of persistent endometrioma by repeat ultrasound. - Transvaginal ultrasound documenting a uterus with no clinically significant abnormalities and presence of at least one ovary with no clinically significant abnormalities (with the exception of endometrioma) at the run-in visit. - Eligible participants experienced moderate to severe endometriosis-related pain, which was defined as at the run-in visit, the participant having an NRS score of =5 for the worst endometriosis related pain during the past menstrual cycle and at randomization, the participant having a mean daily NRS score of =4 for the worst endometriosis related pain during each run-in menstrual cycle. Exclusion Criteria: - History of no relief of endometriosis related pain after any medical therapy or surgery. However, history of partial pain relief, discontinuation due to side effects are not exclusionary. - Known bone diseases (e.g. osteoporosis, Paget's disease and osteomalacia) affecting bone resorption or bone formation markers. - Any significant abnormal findings of heart examinations before randomization. - History of mental illness including occurrence of acute psychosis, bipolar disorders and schizophrenia (except for well-controlled anxiety and/or depression with no changes to interventions for 6 months prior to start of run-in) - History of impulse control disorders including pathological gambling, compulsive buying, hypersexuality, and binge eating or being identified with potential impulse control disorder by the questionnaire for impulsive-compulsive disorders (a score =2 for any sub-questions of Question 3 or a score =1 for any sub-questions of Question 4) prior to randomization. - History of orthostatic hypotension or recurrent syncope.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Quinagolide 360 µg
Vaginal ring containing quinagolide 360 µg for daily releases
Quinagolide 720 µg
Vaginal ring containing quinagolide 720 µg for daily releases
Quinagolide 1080 µg
Vaginal ring containing quinagolide 1080 µg for daily releases
Placebo
Matching placebo

Locations

Country Name City State
United States The Iowa Clinic Ankeny Iowa
United States Austin Area Ob, Gyn and Fertility Austin Texas
United States Johns Hopkins Outpatient Center Baltimore Maryland
United States Montefiore Medical Center Bronx New York
United States SUNY Downstate Medical Center Brooklyn New York
United States Main Line Fertility Center Bryn Mawr Pennsylvania
United States Clinical Trials of South Carolina Charleston South Carolina
United States PMG Research of Charlotte Charlotte North Carolina
United States Northwestern Memorial Hospital Chicago Illinois
United States Corpus Christi Women's Clinic Corpus Christi Texas
United States Omega Research Consultants DeBary Florida
United States Carolina's Women's Research and Wellness Center Durham North Carolina
United States UConn Health Lowell P Weicker Jr Clinical Research Center Farmington Connecticut
United States Rapha Institute For Clinical Research Fayetteville North Carolina
United States Onyx Clinical Research Flint Michigan
United States Penn State Health - Milton S. Hershey Medical Center Hershey Pennsylvania
United States Advances in Health, Inc. Houston Texas
United States Arkansas Primary Care Clinic Little Rock Arkansas
United States Advance Clinical Research Meridian Idaho
United States Marchand Institute for Minimally Invasive Surgery Mesa Arizona
United States Southern Clinical Research Associates Metairie Louisiana
United States Florida Research Center Miami Florida
United States Miami Dade Medical Research Institute Miami Florida
United States South Florida Research Center Miami Florida
United States Vista Health Research Miami Florida
United States Yale Fertility Center New Haven Connecticut
United States Advanced Research Institute New Port Richey Florida
United States Tidewater Clinical Research, Inc. Norfolk Virginia
United States OB/GYN Specialists of Richmond Richmond Virginia
United States Mayo Clinic Rochester Minnesota
United States Valley OB/GYN Clinic, PC Saginaw Michigan
United States Meridien Research Saint Petersburg Florida
United States Wasatch Clinical Research Salt Lake City Utah
United States Medical Center for Clinical Research San Diego California
United States Physician Care Clinical Research Sarasota Florida
United States Omni Fertility Clinical Research LLC Shreveport Louisiana
United States OB/Gyn Associates Silver Spring Maryland
United States Southern Illinois University Springfield Illinois
United States Center of Reproductive Medicine LLC Webster Texas
United States OB•GYN Associates of WNY West Seneca New York
United States Cypress Medical Research Center Wichita Kansas
United States Lyndhurst Clinical Research Winston-Salem North Carolina
United States Unified Women's Clinical Research d/b/a Lyndhurst Clinical Research Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Ferring Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Endometriosis-related Pain. Assessed daily by participants in an e-Diary. NRS is an 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
Changes from baseline to cycle 4.
At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Endometriosis-related Pain on Days With Menstrual Bleeding and for the Worst Endometriosis-related Pain on Days With no Menstrual Bleeding Assessed daily by participants in an e-Diary. NRS is an 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
Days with menstrual bleeding (dysmenorrhea). No menstrual bleeding (non-menstrual pelvic pain) Changes from baseline to cycle 4
At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Endometriosis-related Pain. Assessed daily by participants in an e-Diary. NRS is an 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
Changes over 4 menstrual cycles
From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Dysmenorrhea. Assessed daily by participants in an e-Diary. NRS is an 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
Changes over 4 menstrual cycles
From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Non-menstrual Pelvic Pain. Assessed daily by participants in an e-Diary. NRS is an 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
Changes over 4 menstrual cycles
From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Dyspareunia on Days With Sexual Intercourse. Assessed daily by participants in an e-Diary. NRS is an 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
Changes over 4 menstrual cycles.
From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Frequency of Avoiding Sexual Intercourse Due to Expected Pain The participants recorded daily if they had sexual intercourse, in an e-diary. For the days when participants did not have intercourse, the participant recorded if the reason for not having intercourse was because they expected pain: "Yes" (I did not have intercourse this day, because I expected pain) or "No" (I did not have intercourse this day, but this was not because I expected pain). The numbers represent the cumulative number of days with no intercourse, summed across all participants.
In some cases, there are missing data as not every participant completed the e-diary for 100% of study days.
From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Impact of Endometriosis-related Pain on the Subject's Ability to Function. Assessed daily by participants in an e-Diary. NRS is an 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
Changes over 4 menstrual cycles.
From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in the Mean Weekly Scores of the Endometriosis Health Profile-30 (EHP-30) Pain Impact Domain. Assessed weekly by participants in an e-Diary. EHP-30 is a quality-of-life questionnaire. Score ranges from 0-100 and lower score denotes improvement.
Changes over 4 menstrual cycles.
From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in Vaginal Bleeding Pattern - Number of Days With Bleeding Related to Period The participants recorded daily if they had any vaginal bleeding during the past 24 hours, in an e-diary. Of the participants who had a bleeding, the participant recorded if this was menstrual bleeding: "Yes" (I had a vaginal bleeding that was menstrual bleeding) or "No" (I had a vaginal bleeding that was not menstrual bleeding). The numbers represent the cumulative number of days with vaginal bleeding, summed across all participants.
In some cases, there are missing data as not every participant completed the e-diary for 100% of study days.
From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in Vaginal Bleeding Pattern. The participants recorded daily if they had any vaginal bleeding during the past 24 hours, in an e-diary. Of the participants who had a bleeding, the participant recorded the assessed bleeding volume as either spotting (tiny amount of blood on underwear or panty liners), light bleeding (requiring 1-3 sanitary pads or tampons per day), moderate bleeding (requiring 4-6 sanitary pads or tampons per day), or heavy bleeding (requiring more than 6 sanitary pads or tampons per day). The numbers represent the cumulative number of days with vaginal bleeding, summed across all participants.
In some cases, there are missing data as not every participant completed the e-diary for 100% of study days.
From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Percentage of Days With Mild and/or Strong Rescue Analgesics Used Assessed daily by participants in an e-Diary From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Total and Average Doses of Mild and/or Strong Rescue Analgesics Used Assessed daily by participants in an e-Diary From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Responder Rate Assessed as =30%, =50% and =70% reduction from the baseline in mean daily NRS score for the worst endometriosis-related pain, dysmenorrhea and non-menstrual pelvic pain and for the worst endometriosis-related pain impact From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in the Mean Individual and Total Symptom and Sign Severity Scores Assessed by the Biberoglu and Behrman (B&B) scale which is a 4-point scale with 0=none and 3=severe.
The scores are the mean individual scores.
The B&B scale consists of two parts. The first part of the B&B scale evaluates symptoms of endometriosis (i.e. pain). There are 3 subscales: pelvic pain(A, 0=none and 3=severe), dysmenorrhea (B, 0=none and 3=severe), and dyspareunia(C, 0=none and 3=severe). The total pelvic pain score is the sum of the three scores, i.e. A+B+C, which can range from 0 to 9. The second part of the B&B scale evaluates signs of endometriosis. There are 2 subscales pelvic tenderness (D, 0=none and 3=severe) and induration (E, 0=none and 3=severe) based on findings from a pelvic examination. The total physical pain score is the sum of the two scores, i.e. D+E, which can range from 0 to 6. The total symptom and sign severity score is the sum of all five scores, i.e. A+B+C+D+E, which can range from 0 to 15.
The values are the change from baseline to cycle 4.
At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in the Endometriosis Health Profile-30 (EHP-30) Scores Assessed by the EHP-30 quality-of-life questionnaire completed by participants. Score ranges from 0-100 with lower score denoting improvement. From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in Patient Global Impression of Severity (PGIS) Scores Assessed by the PGIS scale completed by participants. PGIS is a 6-point scale depicting a participant's rating of their current conditions from "good" to "bad".
It ranges from 0 (none) to 5 (very severe).
At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Patient Global Impression of Change (PGIC) Scores Assessed by the PGIC scale completed by participants. PGIC is a 7-point scale depicting a patient's rating of their overall improvement from "good" to "bad". At cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Plasma Concentration of Quinagolide and Metabolites Assessed by blood samples collection Within 5 days after first ring insertion and at around 1 month, 3 months, 3.5 months and 4 months after baseline (each cycle is approximately 28 days)
Secondary Serum Levels of Mid-luteal Phase Progesterone Assessed by blood samples collection At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days)
Secondary Number of Subjects With Serum Mid-luteal Progesterone Levels =25 Nmol/L (7.9 ng/ml) Assessed by blood samples collection At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days)
Secondary Serum Levels of Estradiol Assessed by blood samples collection At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days)
Secondary Serum Levels of Prolactin Assessed by blood samples collection At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days)
Secondary Serum Levels of Thyrotropin (TSH) Assessed by blood samples collection At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days)
Secondary Serum Levels of Insulin-like Growth Factor-1 (IGF-1) Assessed by blood samples collection At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days)
Secondary Changes in Bone Turnover Markers, Determined by Bone Resorption Marker Serum C-terminal Crosslinking Telopeptide of Type 1 Collagen (s-CTx) Assessed by blood samples collection. Changes from baseline to cycle 4 From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in Bone Turnover Markers, Determined by Bone Formation Marker Serum Procollagen Type I N Propeptide (s-PINP) Assessed by blood samples collection. Changes from baseline to cycle 4 From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in ECG Parameters Including PR Interval at Cycle 4 Assessed by 12-lead ECG At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in ECG Parameters Including QRS Duration at Cycle 4 Assessed by 12-lead ECG At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in ECG Parameters Including QT Interval at Cycle 4 Assessed by 12-lead ECG At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Changes in ECG Parameters Including QTcF Interval at Cycle 4 Assessed by 12-lead ECG At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Proportion of Subjects With Abnormal Clinically Significant Echocardiography Findings Indicating Valvular Heart Disease Assessed by echocardiography.
Each echocardiography was to be assessed as normal or abnormal according to American College of Cardiology/American Heart Association guidelines for valvular heart disease. If abnormal, the level of valvular regurgitation and valvular stenosis was specified as mild, moderate or severe and valvular structure was evaluated as well.
Measured at cycle 4.
At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Proportion of Subjects Identified With Potential Impulse Control Disorders Assessed by the questionnaire for impulsive-compulsive disorders completed by participants.
Measured at cycle 4.
At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Frequency and Intensity of Adverse Events Assessed by an Adverse Events Log completed by the Investigator From signing informed consent through study completion, around 8 months
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Albumin Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Alkaline Phosphatase Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Alanine Aminotransferase Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Aspartate Aminotransferase Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Bicarbonate Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Direct Bilirubin Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Bilirubin Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Calcium Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Cholesterol Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Chloride Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Creatinine Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Gamma Glutamyl Transferase Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Glucose Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Potassium Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Lactate Dehydrogenase Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Phosphate Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Protein Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Sodium Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Urate Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Chemistry Parameters: Urea Nitrogen Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Basophils Absolute Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Basophils Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Eosinophils Absolute Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Eosinophils Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Hematocrit Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Hemoglobin Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Lymphocytes Absolute Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Lymphocytes Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Ery. Mean Corpuscular Hemoglobin Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Ery. Mean Corpuscular HGB Concentration Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Ery. Mean Corpuscular Volume Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Monocytes Absolute Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Monocytes Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Neutrophils Absolute Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Neutrophils Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Platelets Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Erythrocytes Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Changes in Circulating Levels of Clinical Haematology Parameters: Leukocytes Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Urinalysis Parameters (Protein, Glucose, Bilirubin, pH, Nitrite, Ketone, Urobilinogen, Blood, Leukocytes, and Specific Gravity) Assessed by urine sample collection (dip-stick test). Overall Urinalysis Result. At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Proportion of Subjects With Markedly Abnormal Changes in Circulating Levels of Clinical Chemistry Parameters Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Proportion of Subjects With Markedly Abnormal Changes in Circulating Levels of Clinical Haematology Parameters Assessed by blood samples collection At baseline and at menstrual cycle 4 (around 4 months)
Secondary Proportion of Subjects With Markedly Abnormal Changes in Urinalysis Parameters Assessed by urine samples collection At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Frequency and Intensity of Ring Acceptability Parameters: Insertion of the Vaginal Ring Assessed by a questionnaire completed by participants, addressing ring insertion From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Frequency and Intensity of Ring Acceptability Parameters: Removal of the Vaginal Ring Assessed by a questionnaire completed by participants, addressing ring removal. From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
Secondary Frequency and Intensity of Ring Acceptability Parameters: Felt the Ring Assessed by a questionnaire completed by participants, addressing any feeling of the ring while the ring is in the body. From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days)
See also
  Status Clinical Trial Phase
Completed NCT04179149 - Enriched Environments in Endometriosis N/A
Completed NCT03654326 - A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034) Phase 2
Recruiting NCT04554693 - The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery Phase 4
Recruiting NCT06214260 - Menstrual Blood Proteomic Profile in Women With Endometriosis (PROTEO-ENDO) Study
Recruiting NCT05978414 - Functional Links Between the Temporomandibular Joint and the Pelvis in Gynecology N/A
Recruiting NCT05152264 - Transcutaneous Electrical Nerve Stimulation for Endometriosis-related Chronic Pain N/A
Recruiting NCT06414083 - Histologic Comparison of Ablative Techniques for Endometriosis N/A
Completed NCT04440397 - Relationship Between Endoplasmic Reticulum Stress and Pain in Patients With Endometriosis
Completed NCT04370444 - Pathways for Patient-centered Diagnosis and Management of Endometriosis-associated Deep Dyspareunia N/A
Recruiting NCT05367258 - Umbilical Endometriosis: a Comparison of Medical and Surgical Therapy and Pathogenetic Considerations
Completed NCT05527002 - Thoracic Endometriosis: A Cohort Study
Recruiting NCT05754190 - Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
Recruiting NCT04728152 - Evaluation of miRNAs in Endometriosis
Completed NCT04883073 - Impact on Quality of Life of "Endo-App" (ELEA) N/A
Active, not recruiting NCT04204707 - Patient Reported Outcomes After Surgery for Rectal Endometriosis
Recruiting NCT06438744 - The Role of Thread Embedding Acupuncture for Pain and Quality of Life in Endometriosis Patients N/A
Recruiting NCT06286371 - Pelvic Neuro-Angiogenesis in Deep Endometriosis N/A
Not yet recruiting NCT04491305 - EHP-5 in Preoperative Assessment in Women With Endometriosis
Recruiting NCT05433909 - Microbiota and Immunoassay in Women With and Without Endometriosis: a Pilot Study N/A
Recruiting NCT05496218 - Metabolomic Profile in Women With and Without Endometriosis N/A